Title:
PHARMACEUTICAL COMPOSITION CONTAINING α-LIPOIC ACID, EVOGLIPTIN OR MIXTURE THEREOF AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE
Document Type and Number:
WIPO Patent Application WO/2019/124607
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition containing α-lipoic acid, evogliptin or a mixture thereof as an active ingredient for preventing or treating non-alcoholic fatty liver disease. According to the present invention, α-lipoic acid, evogliptin, or a mixture thereof reduces expression of enzymes involved in synthesis of neutral fat and increases expression of enzymes involved in degradation of neutral fat in an animal model of non-alcoholic fatty liver disease induced by a high fat diet, thereby reducing fat accumulation in hepatocytes. Also, α-lipoic acid, evogliptin, or a mixture thereof can reduce cell death, oxidative stress, and vitamin D receptor expression, and inhibit expression of a protein associated with autophagy, thereby reducing autophagy. Accordingly, α-lipoic acid, evogliptin, or a mixture thereof of the present invention having the above-mentioned effects can be effectively used as a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease and a health food composition for preventing or treating non-alcoholic fatty liver disease.
Inventors:
KIM SOO KYOUNG (KR)
Application Number:
PCT/KR2017/015370
Publication Date:
June 27, 2019
Filing Date:
December 22, 2017
Export Citation:
Assignee:
GYEONGSANG NATIONAL UNIV HOSPITAL (KR)
International Classes:
A61K31/385; A23L33/10; A61K31/496
Foreign References:
| KR20060072603A | 2006-06-28 |
Other References:
JUNG, TAE SIK: "a-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats", LIVER INTERNATIONAL, 2012, pages 1565 - 1573, XP055620921
YANG, YI: "Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxOl and Nrf2 via the SIRT1/LKB1/AMPK pathway", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2014, pages 1207 - 1217, XP029080513
PARK, KEUN-GYU: "Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways", HEPATOLOGY, vol. 48, no. 5, 2008, pages 1477 - 1486, XP002659185
KIM, MI-KYUNG: "Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models", A RCHIVES OF PHARMACAL RESEARCH, 24 November 2016 (2016-11-24), pages 268 - 281, XP036164025
YANG, YI: "Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxOl and Nrf2 via the SIRT1/LKB1/AMPK pathway", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2014, pages 1207 - 1217, XP029080513
PARK, KEUN-GYU: "Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways", HEPATOLOGY, vol. 48, no. 5, 2008, pages 1477 - 1486, XP002659185
KIM, MI-KYUNG: "Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models", A RCHIVES OF PHARMACAL RESEARCH, 24 November 2016 (2016-11-24), pages 268 - 281, XP036164025
Attorney, Agent or Firm:
TAEBAEK INTELLECTUAL PROPERTY LAW FIRM (KR)
Download PDF: